XORTX Therapeutics Inc.
XRTX
$0.87
-$0.1026-10.55%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -34.51% | 62.44% | |||
| Depreciation & Amortization | -21.52% | 2.80% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.08% | 50.99% | |||
| Operating Income | 35.08% | -50.99% | |||
| Income Before Tax | -445.09% | 105.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -445.09% | 105.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -445.09% | 105.63% | |||
| EBIT | 35.08% | -50.99% | |||
| EBITDA | 32.74% | -46.59% | |||
| EPS Basic | -445.05% | 104.72% | |||
| Normalized Basic EPS | -445.36% | 104.71% | |||
| EPS Diluted | -445.05% | 104.72% | |||
| Normalized Diluted EPS | -445.36% | 104.71% | |||
| Average Basic Shares Outstanding | 0.00% | 19.52% | |||
| Average Diluted Shares Outstanding | 0.00% | 19.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
